Esperion Therapeutics’ (ESPR) Buy Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Esperion Therapeutics (NASDAQ:ESPR) in a research note published on Wednesday morning,Benzinga reports. HC Wainwright currently has a $16.00 price objective on the biopharmaceutical company’s stock.

ESPR has been the subject of several other research reports. StockNews.com lowered shares of Esperion Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, November 15th. Needham & Company LLC decreased their price target on Esperion Therapeutics from $8.00 to $6.00 and set a “buy” rating for the company in a research report on Tuesday, August 13th.

Esperion Therapeutics Price Performance

NASDAQ ESPR opened at $2.80 on Wednesday. The company has a fifty day moving average price of $2.11 and a 200-day moving average price of $2.16. Esperion Therapeutics has a 1 year low of $1.27 and a 1 year high of $3.40. The firm has a market cap of $551.71 million, a price-to-earnings ratio of -4.38 and a beta of 0.96.

Institutional Trading of Esperion Therapeutics

Several hedge funds have recently added to or reduced their stakes in ESPR. Eaton Financial Holdings Company LLC bought a new position in shares of Esperion Therapeutics during the 3rd quarter valued at approximately $73,000. Barclays PLC lifted its stake in Esperion Therapeutics by 99.6% in the third quarter. Barclays PLC now owns 309,671 shares of the biopharmaceutical company’s stock valued at $510,000 after purchasing an additional 154,509 shares during the last quarter. Geode Capital Management LLC grew its holdings in Esperion Therapeutics by 4.1% during the third quarter. Geode Capital Management LLC now owns 4,331,314 shares of the biopharmaceutical company’s stock valued at $7,148,000 after purchasing an additional 171,609 shares during the period. Public Employees Retirement System of Ohio purchased a new stake in Esperion Therapeutics in the third quarter worth $606,000. Finally, Anson Funds Management LP bought a new stake in shares of Esperion Therapeutics in the third quarter valued at $540,000. Institutional investors own 47.39% of the company’s stock.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.